No Image

USSOCOM Awards Vricon Foreign Comparative Test Contract

<h3 align="center">Vricon to increase the resolution and accuracy of SOCOM’s 3D geospatial data</h3> <p>McLean, Virginia, Nov. 09, 2017 (GLOBE NEWSWIRE) — The <a href="https://www.globenewswire.com/Tracker?data=FlAvUI6EjlKTuc6PeDdHhAdQ3faXAVnL4phj_zXhZU2Og4l4-hbRwRVpNLPQZbV8koUrqLM4rjj4EfOpA2ZMUKbBbv-d1fYIH108GqUEXsM=" rel="nofollow">US S...
read more
No Image

Nasdaq Wins RiskTech100® Best Operational Risk & GRC Category

<div> <p align="center"><em>Awarded by </em><a href="https://www.globenewswire.com/Tracker?data=d7PntYkxi39KUo8vCYIQGT_XLZ4ja3exBx4KFGGojxBFB0tPYYapjU1xiYhbi57cZJcl00e65DpMlu1gaZ4g_WdgjhLa2HzmAHIftxoeMgo=" rel="nofollow"><em>Chartis</em></a><em><a href="https...
read more
No Image

Disruptive Semiconductor Technology Leader Luxcore Signs Multi-year Colocation Deal with INAP

<div> <p align="justify"><em>Luxcore selects INAP to support their ground breaking second generation LambdaRouter<sup>TM</sup> — the first full wavelength optical router.</em></p> <p align="justify"><em>INAP chosen for its global presence in strategic ma...
read more
No Image

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

<div> <ul type="disc"> <li><strong>Top-line results are expected to be announced in mid-2018</strong></li> <li><strong>The Phase III study evaluating RHB-104 for Crohn’s disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is e...
read more
No Image

VistaJet Customers Grow by 50% in the Middle East as the Company Expands Its Reach

<div> <div> <p align="center"><strong>The leader in global business aviation increases its offering </strong><strong>to continue positive momentum in the region</strong></p> <ul type="disc"> <li><strong>New Program hours doubled year over year</strong></li> <...
read more
No Image

Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering

<div> <p align="left">MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based o...
read more